Publications in collaboration with researchers from Hospital Universitario La Paz (24)

2023

  1. Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease

    Revista Espanola de Patologia, Vol. 56, Núm. 3, pp. 158-167

2019

  1. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

    British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807

2017

  1. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

  2. The syndrome of central hypothyroidism and macroorchidism: IGSF1 controls TRHR and FSHB expression by differential modulation of pituitary TGFβ and Activin pathways

    Scientific Reports, Vol. 7

  3. Whole Exome Sequencing reveals new candidate genes in host genomic susceptibility to Respiratory Syncytial Virus Disease

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial

    Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899

  2. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

2015

  1. Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation

    Haematologica, Vol. 100, Núm. 5, pp. e200-e203

  2. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

    Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69

  3. Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations

    International Journal of Cancer, Vol. 137, Núm. 8, pp. 1870-1878

2014

  1. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

  2. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

  3. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial

    British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336

  4. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation

    Leukemia, Vol. 28, Núm. 6, pp. 1334-1340

2013

  1. Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

    Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952

2012

  1. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    Blood, Vol. 120, Núm. 13, pp. 2581-2588

2011

  1. Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study

    Journal of Clinical Endocrinology and Metabolism, Vol. 96, Núm. 2

2010

  1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

    The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941

1998

  1. Autotransplantation in chronic myeloid leukemia [1]

    Bone Marrow Transplantation

1997

  1. Autologous transplantation of peripheral stem cells in patients with chronic myeloid leukemia after mobilization with high-dose hydroxyurea

    Sangre, Vol. 42 Suppl 1, pp. 21-23